← Back to Search

Brain Glymphatic Imaging for Parkinson’s Disease

Phase < 1

Waitlist Available

Led By Manus J Donahue, Ph.D.

Research Sponsored by Vanderbilt University Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosis of Parkinson's Disease or controls

Be older than 18 years old

Must not have

Prior stroke

Unstable diabetes

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, under anesthesia

Awards & highlights

No Placebo-Only Group

Summary

This trial is looking at whether or not a central nervous system lymphatic drainage system exists in humans, and if it does, whether it could help with conditions like stroke, multiple sclerosis, Parkinson's disease, and Alzheimer's disease related dementia.

Who is the study for?

This trial is for individuals diagnosed with Parkinson's Disease or healthy controls willing to undergo PET and MRI imaging. It excludes those who have used stimulants recently, have unstable diabetes, a history of stroke, claustrophobia, prior chemotherapy for cancer treatment, traumatic brain injury, or any unstable medical condition.

What is being tested?

[11C]-PIB is being tested as part of an effort to improve imaging methods that can detect issues in the brain's lymphatic drainage system. This could be important for understanding and treating conditions like Parkinson's disease and Alzheimer's related dementia.

What are the potential side effects?

The side effects are not explicitly listed here but generally include risks associated with PET and MRI scans such as discomfort from lying still during the scan or allergic reactions to contrast agents if used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with Parkinson's Disease.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have had a stroke before.

Select...

My diabetes is not well-controlled.

Select...

I have previously undergone chemotherapy for cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, under anesthesia

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, under anesthesia

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, under anesthesia for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Pulmonary Diffusing Capacity

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Parkinson's Disease participants with MCIExperimental Treatment1 Intervention

Patient volunteers will also undergo a C-11 PiB PET scan. This procedure utilizes a common radiotracer that is used routinely in clinical PET scans and will be purchased here from PETNET and certified for human use. All PET scans will be performed by a certified PET technologist at the Vanderbilt University Institute of Imaging Science.

0 / 4Eligibility criteria met